IFNA1 and COVID-19: While several smaller clinical trials have reported mixed results based on diverse primary and secondary outcomes on the therapeutic benefits of IFN administration in single or cotreatment regimens in mild-moderate as well as on severe hospitalized and ambulatory patients, the WHO SOLIDARTY Consortium Trial is the largest clinical trial till-date that evaluated the therapeutic effects of IFN-β1a administration (and other drugs including HCQ, Remdesivir and LPV) in several thousand COVID-19 patients.